Anika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key MilestoneGlobeNewsWire • 05/30/23
Anika Therapeutics (ANIK) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/10/23
Anika to Participate in the 22nd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/12/23
Anika Continues to Expand Addressable Market for Tactoset® Injectable Bone Substitute with Additional 510(k) Clearance from FDAGlobeNewsWire • 04/03/23
Anika Highlights Products in High Growth Segments of Joint Preservation during the 2023 AAOS Annual MeetingGlobeNewsWire • 03/08/23
Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/06/23
Anika to Issue Fourth Quarter and Year-End 2022 Financial Results on Monday, March 6, 2023GlobeNewsWire • 02/21/23
Anika Announces First Surgeries Performed Using the New RevoMotion™ Reverse Shoulder Arthroplasty System and Commences Limited Market Release in the United StatesGlobeNewsWire • 02/13/23
Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 01/17/23
Anika Therapeutics (ANIK) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/09/22
Anika's Cingal® Successfully Achieves Primary Endpoint in Third Phase III StudyGlobeNewsWire • 11/01/22
Anika to Issue Third Quarter 2022 Financial Results on Tuesday, November 8, 2022GlobeNewsWire • 10/25/22